Read code	Description
K0400	Acute renal failure
K040.00	Acute renal tubular necrosis
K041.00	Acute renal cortical necrosis
K042.00	Acute renal medullary necrosis
K043.00	Acute drug-induced renal failure
K044.00	Acute renal fail urin obstruct
K04y.00	Other acute renal failure
K04z.00	Acute renal failure NOS
Kyu2000	[X]Other acute renal failure
G500400	Acute pericarditis - uraemic
K101000	Acute pyelonephritis without medullary necrosis
K101100	Acute pyelonephritis with medullary necrosis
K0411	ARF - Acute renal failure
K0412	Acute kidney injury
K043000	Acute renal failure due to ACE inhibitor
K043100	Acute renal failure induced by aminoglycoside
K043300	Acute renal failure induced by cyclosporin A
K043400	Acute renal failure induced by non-steroid anti-inflamm drug
K045.00	Acute renal failure due to non-traumatic rhabdomyolysis
K046.00	Acute renal failure induced by toxin
K04B.00	Acute renal failure due to traumatic rhabdomyolysis
K04C.00	Acute kidney injury stage 1
K04D.00	Acute kidney injury stage 2
K04E.00	Acute kidney injury stage 3

Supplementary Table 1. Read codes for AKI.

Baseline eGFR	Cohort	Person-years	Incident AKI cases (N)	Incidence rate per 10,000 person-years	HR [*] (95% CI)	p value
AKI Method A						
Any eGFR	Warfarin (N=7129)	11,201.1	75	67.0	1.0 (ref)	
	Rivaroxaban (N=6436)	9019.2	70	77.6	1.18 (0.85–1.65)	0.33
$eGFR > 50mL/min/1.73m^2$	Warfarin (N=6043)	9621.0	48	49.9	1.0 (ref)	
	Rivaroxaban (N=5547)	7847.6	46	58.6	1.16 (0.77–1.76)	0.48
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1086)	1580.1	27	170.9	1.0 (ref)	
	Rivaroxaban (N=889)	1171.7	24	204.8	1.15 (0.64–2.06)	0.64
AKI Method B						
Any eGFR	Warfarin (N=7129)	11,022.7	278	252.2	1.0 (ref)	
-	Rivaroxaban (N=6436)	8918.1	175	196.2	0.76 (0.62–0.92)	< 0.01
eGFR >50mL/min/1.73m ²	Warfarin (N=6043)	9484.6	206	217.2	1.0 (ref)	
	Rivaroxaban (N=5547)	7760.2	133	171.4	0.74 (0.59–0.92)	0.01
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1086)	1538.1	72	468.1	1.0 (ref)	
	Rivaroxaban (N=889)	1157.9	42	362.7	0.81 (0.54–1.20)	0.28

Supplementary Table 2. Incidence rate per 10,000 person-years of AKI and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function: <u>on-treatment analysis.</u>

Note: Method A was based on Read codes, and Method B was based on the Aberdeen algorithm.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA2DS2VASc score, and use of antiplatelets/anti-infectives.

Baseline eGFR	Cohort	Person- years	Incident AKI cases (N)	Incidence rate per 10,000 person-years	HR* (95% CI)	p value
AKI Method A						
Any eGFR	Warfarin (N=7230)	14903.4	104	69.8	1.0 (ref)	
	Rivaroxaban (N=7045)	12,064.0	93	77.1	1.13 (0.85–1.50)	0.4
$eGFR > 50 mL/min/1.73m^2$	Warfarin (N=6124)	12,806.7	67	52.32	1.0 (ref)	
	Rivaroxaban (N=6081)	10,567.3	62	58.67	1.12 (0.79–1.58)	0.54
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1106)	2096.7	37	176.5	1.0 (ref)	
	Rivaroxaban (N=964)	1496.7	31	207.1	1.14 (0.69–1.87)	0.61
AKI Method B						
Any eGFR	Warfarin (N=7225)	14,580.6	345	236.6	1.0 (ref)	
	Rivaroxaban (N=7020)	11,861.3	216	182.1	0.77 (0.65–0.91)	< 0.01
eGFR >50 mL/min/1.73m ²	Warfarin (N=6119)	12,563.2	259	206.2	1.0 (ref)	
	Rivaroxaban (N=6057)	10,390.5	167	160.7	0.76 (0.63-0.93)	0.01
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1106)	2017.5	86	426.3	1.0 (ref)	
	Rivaroxaban (N=963)	1470.9	49	333.1	0.82 (0.57-1.18)	0.28

Supplementary Table 3. Incidence rate per 10,000 person-years of AKI and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function: a<u>s-treated analysis.</u>

Note: Method A was based on Read codes, and Method B was based on the Aberdeen algorithm.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

Supplementary Table 4. Incidence rate per 10,000 person-years of <u>severe AKI (using AKI Method B – see footnote)</u> and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function (intention-to-treat analysis).

Baseline eGFR	Cohort	Person-years	Incident	Incidence rate	HR* (95% CI)	p value
			severe AKI	per 10,000		
			cases (N)	person-years		
Any eGFR	Warfarin (N=7129)	19,492.2	104	53.4	1.0 (ref)	
	Rivaroxaban (N=6436)	13,686.8	54	39.5	0.74 (0.53–1.04)	0.08
eGFR >50mL/min/1.73m ²	Warfarin (N=6043)	16,946.4	78	46.0	1.0 (ref)	
	Rivaroxaban (N=5547)	11,963.1	38	31.8	0.68 (0.46–1.01)	0.06
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1086)	2545.8	26	102.1	1.0 (ref)	
	Rivaroxaban (N=889)	1723.6	16	92.8	0.95 (0.50-1.82)	0.88

Note: Method B was based on the Aberdeen algorithm. Severe AKI was defined as stage 2 or 3 AKI.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

Supplementary Table 5. Incidence rate per 10,000 person-years of <u>severe AKI (using AKI Method B – see footnote)</u> and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function (on-treatment analysis).

Baseline eGFR	Cohort	Person-years	Incident severe AKI	Incidence rate per 10,000	HR [*] (95% CI)	p value
			cases (N)	person-years		
Any eGFR	Warfarin (N=7129)	11,022.7	63	57.2	1.0 (ref)	
	Rivaroxaban (N=6436)	8918.1	40	44.9	0.81 (0.54–1.21)	0.30
$eGFR > 50mL/min/1.73m^2$	Warfarin (N=6043)	9484.6	45	47.5	1.0 (ref)	
	Rivaroxaban (N=5547)	7760.2	26	33.5	0.68 (0.41–1.11)	0.13
eGFR \leq 50 mL/min/1.73m ²	Warfarin (N=1086)	1538.1	18	117.0	1.0 (ref)	
	Rivaroxaban (N=889)	1157.9	14	120.9	1.10 (0.53–2.29)	0.79

Note: Method B was based on the Aberdeen algorithm. Severe AKI was defined as stage 2 or 3 AKI.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

Supplementary Table 6. Incidence rate per 10,000 person-years of <u>severe AKI (using AKI Method B – see footnote)</u> and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function (as-treated analysis).

Baseline eGFR	Cohort	Person-	Incident	Incidence rate	HR [*] (95% CI)	p value
		years	severe AKI	per 10,000		
			cases (N)	person-years		
Any eGFR	Warfarin (N=7225)	14,580.6	76	52.12	1.0 (ref)	
	Rivaroxaban (N=7020)	11,861.3	49	41.31	0.82 (0.57-1.18)	0.29
eGFR >50mL/min/1.73m ²	Warfarin (N=6119)	12,563.2	52	41.39	1.0 (ref)	
	Rivaroxaban (N=6057)	10,390.5	35	33.68	0.82 (0.53-1.27)	0.38
$eGFR \leq 50 \text{ mL/min/1.73m}^2$	Warfarin (N=1106)	2017.5	24	118.96	1.0 (ref)	
	Rivaroxaban (N=963)	1470.9	14	95.18	0.85 (0.43–1.69)	0.65

Note: Method B was based on the Aberdeen algorithm. Severe AKI was defined as stage 2 or 3 AKI.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

Supplementary Table 7. Incidence rate per 10,000 person-years of AKI and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, stratified by baseline renal function (ITT analysis): <u>Fine and Gray models</u>.

Cohort	Person-years	Incident AKI cases (N)	Incidence rate per 10,000 person-years	SHR [*] (95% CI)	p value
AKI Method A					
Warfarin (N=7129)	20,027.6	136	67.9	1.00 (ref)	
Rivaroxaban (N=6436)	13,917.5	113	81.2	1.15 (0.89–1.47)	0.29
AKI Method B (any AKI)					
Warfarin (N=7129)	19,492.2	457	234.5	1.00 (ref)	
Rivaroxaban (N=6436)	13,686.8	266	194.4	0.77 (0.66–0.89)	< 0.01
AKI Method B (severe AKI)					
Warfarin (N=7129)	19,492.2	104	53.4	1.00 (ref)	
Rivaroxaban (N=6436)	13,686.8	54	39.5	0.72 (0.51–1.00)	0.05

Note: Method A was based on Read codes, and Method B was based on the Aberdeen algorithm. Severe AKI was defined as stage 2 or 3 AKI. (stage 1 was included as a competing risk).

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

Baseline eGFR	Cohort	Person- years	Incident AKI cases (N)	Incidence rate per 10,000 person-years	HR [*] (95% CI)	p value
AKI algorithm (meeting criterion 2 or 3) ^{\dagger}						
Any eGFR	Warfarin (N=7129)	20,134.2	60	29.8	1.0 (ref)	
	Rivaroxaban (N=6436)	14,029.4	21	15.0	0.50 (0.30-0.84)	0.01
eGFR >50	Warfarin (N=6043)	17,455.3	38	21.8	1.0 (ref)	
	Rivaroxaban (N=5547)	12,236.7	15	12.3	0.53 (0.28-1.00)	0.05
eGFR ≤50	Warfarin (N=1086)	2678.8	22	82.1	1.0 (ref)	
	Rivaroxaban (N=889)	1792.7	6	33.5	0.36 (0.14-0.97)	0.04
AKI algorithm (meeting criterion 3) [‡]						
Any eGFR	Warfarin (N=7129)	20,159.0	37	18.4	1.0 (ref)	
	Rivaroxaban (N=6436)	14,041.6	11	7.8	0.41 (0.20-0.84)	0.01
eGFR >50	Warfarin (N=6043)	17,478.0	19	10.9	1.0 (ref)	
	Rivaroxaban (N=5547)	12,243.7	9	7.3	0.70 (0.29–1.67)	0.42
eGFR ≤50	Warfarin (N=1086)	2681.1	18	67.1	1.0 (ref)	
	Rivaroxaban (N=889)	1797.9	2	11.1	0.15 (0.03-0.71)	0.02


Supplementary Table 8. Incidence rate per 10,000 person-years of AKI and HR (95% CI) comparing AKI in the rivaroxaban vs. warfarin cohorts, overall and stratified by baseline renal function: <u>more stringent method B criteria</u>.

Note: Method A was based on Read codes, and Method B was based on the Aberdeen algorithm.

^{*}Adjusted for age, sex, baseline eGFR (both as categorical and continuous variables), number of previous eGFR measurements at baseline, Townsend index, polymedication, smoking, body mass index, use of health services in the year before baseline (PCP visits, referrals and hospitalizations), comorbidity (ischemic heart disease, cancer, diabetes, heart failure and liver disease), frailty, CHA₂DS₂VASc score, and use of antiplatelets/anti-infectives.

[†]Serum creatinine \geq 1.5 times higher than the lowest creatinine within 7 days (criterion 2) or serum creatinine >26 µmol/L higher than the lowest creatinine within 48 hours (criterion 3).

^{*}Serum creatinine >26 μ mol/L higher than the lowest creatinine within 48 hours (criterion 3).



Supplementary Figure 1. AKI cases identified by the two case identification definitions. AKI, acute kidney injury